The latest from NuvOx

17 hours ago

NuvOx Pharma LLC Announces Receipt of Qualified Person’s Declaration Equivalence to UK / EU GMP for Investigational Medical Products

Tucson, AZ, September 6th, 2024 – NuvOx Pharma LLC, a wholly owned subsidiary of NuvOx Therapeutics Inc. (together, “NuvOx”) announced...

Jul 11

NuvOx Pharma LLC Announces Authorization of ARDS Trial from Health Canada

Tucson, AZ, June 30th, 2024 – NuvOx Pharma LLC (“NuvOx”) announced that it has received authorization from Health Canada for its EXTEND:...

Jan 8

NuvOx Pharma Announces Issuance of a New Patent

Tucson, AZ, January 2, 2024 - NuvOx Pharma has been issued US Patent No. 11,857,627, entitled “Fractionated Radiotherapy and...

Nov 2, 2023

NuvOx Announces Contract to Support NOVEL Trial

Tucson, AZ, USA, October 31, 2023 - NuvOx Pharma (NuvOx), a clinical stage biotechnology company developing a first-in-class therapeutic...

Oct 2, 2023

NuvOx Therapeutics Wins Most Fundable Company by Pepperdine Graziadio Business School

Tucson, AZ, September 28th, 2023 NuvOx Therapeutics (“NuvOx”) is delighted to announce that it achieved the Gold Level recognition on the...

Sep 25, 2023

NuvOx Closed Oversubscribed Convertible Notes

Tucson, AZ, September 18th, 2023 NuvOx Therapeutics (“NuvOx”) announced that it has closed an oversubscribed convertible notes round,...

Aug 30, 2023

NuvOx Announces Publication of Research Article in Cancer Research Communication

Tucson, AZ, August 28th, 2023 NuvOx Pharma announced publication of a research article, “Dodecafluoropentane Emulsion as a...

Aug 14, 2023

NuvOx Announces BARDA Partnership for a Phase Ib ARDS/COVID Trial in Canada

Tucson, AZ, August 4th, 2023 - NuvOx Pharma (NuvOx), a clinical stage biotechnology company developing a first-in-class therapeutic to...

Jun 7, 2023

NuvOx Announces Glioblastoma Patient Treatment for Phase IIb RESTORE Trial

Tucson, AZ, May 30, 2023 - NuvOx Pharma (NuvOx), a clinical stage biotechnology company developing a first-in-class therapeutic to treat...

Apr 19, 2023

NuvOx Receives SPAN Grant

NuvOx Receives SPAN Grant to Conduct Late-stage Preclinical Studies of Putative Neuroprotectants Combined with Reperfusion Tucson, AZ, ...

Mar 5, 2023

NuvOx Newly Issued US Patent

The issued patent has claims for methods of use of DDFPe for stroke treatment.

Oct 11, 2022

NuvOx Pharma Presents at AZ BIO White Hat Event

May 19, 2022

NuvOx Pharma Announces Issuance of a New Patent

Award of this patent broadens NuvOx’s extensive patent portfolio of perfluorocarbon-based therapeutic formulations to reverse hypoxia.

May 9, 2022

NuvOx Appoints Dr. Robert King to SAB

Tucson, AZ, May 9th, 2022 – https://www.pr.com/press-release/861001 NuvOx Pharma, a clinical stage biotechnology company developing a...

May 9, 2022

NuvOx Technology Featured in Prominent Peer Review Journal

Tucson, AZ, April 19, 2022 -- https://www.pr.com/press-release/859633 NuvOx Pharma’s technology, which is developed as a first-in-class...

May 9, 2022

NuvOx Finalizes Facility Certification, Poising for Phase IIb Trials

Tucson, AZ, April 17, 2022 -- https://www.pr.com/press-release/859467 NuvOx Pharma, a clinical stage biotechnology company developing a...

Mar 4, 2022

NuvOx Receives Notice from the Breakthrough DOD Award for its Immuno-Oncology Program

On February 11th, 2022,-- https://www.pr.com/press-release/859467 NuvOx Pharma received notice from the Department of Defense (DOD)...

Feb 9, 2022

NuvOx to Participate in the BIO CEO Investor Conference

Tucson, AZ, February 10, 2022 – NuvOx Pharma, a clinical stage biotechnology company developing a first-in-class therapeutic to treat...

Jan 12, 2022

NuvOx to Present at Various Bio Forums in JPM Week Tucson, AZ, January 7, 2022

Tucson, AZ, January 7, 2022 – NuvOx Pharma, a clinical stage biotechnology company developing a first-in-class therapeutic to treat...

Oct 15, 2021

NuvOx Pharma Receives Phase I STTR Grant from NINDS for Preclinical Studies in Stroke

Tucson, AZ, October 12, 2021 --(PR.com)-- NuvOx Pharma, a Tucson based biotechnology company, has received a $478,000 NIH Phase I Small...